Skip to Main Content

San Diego synthetic biology company Synthorx is entering the drug discovery game with a couple extra base pairs up its sleeve: It’s developing new biologic drugs with an expanded DNA alphabet, adding synthetic nucleotides X and Y to the standard lineup of A, C, G, and T.

The company just raised $10 million, on top of $6 million in investment it collected back in 2014.


CEO Court Turner spoke with STAT about the company’s technology — and its plans for developing drugs for diabetes and other conditions with that loaded-up DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!